Status:
COMPLETED
The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients
Lead Sponsor:
Federation Francophone de Cancerologie Digestive
Collaborating Sponsors:
ARCAGY/ GINECO GROUP
GERCOR - Multidisciplinary Oncology Cooperative Group
Conditions:
Cancer
COVID
Eligibility:
All Genders
18+ years
Brief Summary
Since December 2019, China and then the rest of the world have been affected by the rapid development of a new coronavirus, SARS-CoV-2 (severe acute respiratory syndrome corona virus 2). The disease c...
Detailed Description
Since December 2019, China and then the rest of the world have been affected by the rapid development of a new coronavirus, SARS-CoV-2 (severe acute respiratory syndrome corona virus 2). The disease c...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- Patient undergoing treatment or under surveillance or recently diagnosed and who has not yet started treatment for cancer at one of the following locations : digestive (esophagus, stomach, colorectal, small intestine, pancreas, biliary tract, Vater's ampulla, liver, GIST, neuroendocrine tumour, anal canal, primary peritoneum, appendix), thoracic (non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), mesothelioma), head and neck (oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, salivary glands, sinus), gynecological (breast, ovary, cervix, endometrium, vulva), central nervous system, dermatological, urological (prostate, kidney, bladder and upper urinary tract, external genitals)
- Patient with PCR and/or serology and/or CT-scan confirmed SARS-COV-2 infection or with suggestive COVID-19 syndrome (fever, fatigue, body aches, headache, cough, dyspnea, sudden onset of anosmia or ageusia in the absence of rhinitis or nasal obstruction) without biological or CT-scan confirmation during the period of March 1, 2020 to September 30, 2020.
- Inpatient or outpatient
- Patient informed of the research and, by way of derogation, patient treated in an emergency situation
Exclusion
- Patients whose cancer in the cohort was treated curatively more than 5 years ago, with no evidence of recurrence at the time of the SARS-COV-2 infection.
- Patient expressing opposition to participating in the cohort
- Patient subject to a protective measure (patient under guardianship or curatorship)
Key Trial Info
Start Date :
April 3 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2021
Estimated Enrollment :
1523 Patients enrolled
Trial Details
Trial ID
NCT04397575
Start Date
April 3 2020
End Date
September 30 2021
Last Update
April 4 2022
Active Locations (148)
Enter a location and click search to find clinical trials sorted by distance.
1
Ch D'Abbeville
Abbeville, France
2
CHU - Hôpital Sud
Amiens, France
3
CHU - Hôtel Dieu
Angers, France
4
Hôpital Privé
Antony, France